ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2009
Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Changing paradigm of antibiotic resistance amongst Escherichia coli isolates in Indian pediatric population.PloS one · 2019Trial
- General Practitioner Antimicrobial Stewardship Programme Study (GAPS): protocol for a cluster randomised controlled trial.BMC family practice · 2016Trial
- Article
- Maternal Colonization, Perinatal Exposure, and Neonatal Acquisition of Resistant Enterobacterales.Open forum infectious diseases · 2026Article
- Phenotypic and Genotypic Characteristics of Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- Molecular Epidemiological Characterisation of ESBL- and Plasmid-Mediated AmpC-ProducingTropical medicine and infectious disease · 2022Article
- KPC-3-Producing Serratia marcescens Outbreak between Acute and Long-Term Care Facilities, Florida, USA.Emerging infectious diseases · 2020Article
- Molecular Epidemiology of Ceftriaxone Non-Susceptible Enterobacterales Isolates in an Academic Medical Center in the United States.Open forum infectious diseases · 2019Article
- Diversity, Virulence, and Clinical Significance of Extended-Spectrum β-Lactamase- and pAmpC-ProducingFrontiers in microbiology · 2019Article
- Host-Specific Patterns of Genetic Diversity among IncI1-Iγ and IncK Plasmids Encoding CMY-2 β-Lactamase in Escherichia coli Isolates from Humans, Poultry Meat, Poultry, and Dogs in Denmark.Applied and environmental microbiology · 2016Article
- Escherichia coli β-Lactamases: What Really Matters.Frontiers in microbiology · 2016Review
- NDM-1-Producing Citrobacter freundii, Escherichia coli, and Acinetobacter baumannii Identified from a Single Patient in China.Antimicrobial agents and chemotherapy · 2015Article
- Dominance of IMP-4-producing enterobacter cloacae among carbapenemase-producing Enterobacteriaceae in Australia.Antimicrobial agents and chemotherapy · 2015Article
- Escherichia coli sequence type 354 coproducing CMY-2 cephalosporinase and RmtE 16S rRNA methyltransferase.Antimicrobial agents and chemotherapy · 2014Article
- Long-term dissemination of acquired AmpC β-lactamases among Klebsiella spp. and Escherichia coli in Portuguese clinical settings.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2014Article
- Prevalence and pathogenesis of extended-spectrum beta-lactamase producing Escherichia coli causing urinary tract infection in hospitalized patients.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Article
- Cefotaxime for the detection of extended-spectrum β-lactamase or plasmid-mediated AmpC β-lactamase and clinical characteristics of cefotaxime-non-susceptible Escherichia coli and Klebsiella pneumoniae bacteraemia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Article
- Features of infections due to Klebsiella pneumoniae carbapenemase-producing Escherichia coli: emergence of sequence type 131.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Article
- Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States.Antimicrobial agents and chemotherapy · 2012Article
- Multicenter evaluation of a new DNA microarray for rapid detection of clinically relevant bla genes from beta-lactam-resistant gram-negative bacteria.Antimicrobial agents and chemotherapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundKnowledge of the clinical features of infections caused by Escherichia coli strains that produce plasmid-mediated AmpC beta-lactamase is limited. Of the several groups of plasmid-mediated AmpC beta-lactamases, CMY-type beta-lactamase is the most common in the United States.
methodsWe prospectively identified patients infected or colonized with E. coli strains that produce CMY-type beta-lactamase, and we collected clinical data over a 7-month period. A retrospective cohort study was performed to identify features associated with these cases. Patients with extended-spectrum beta-lactamase-producing E. coli were used as a control group. Pulsed-field gel electrophoresis, plasmid analysis, and phylogenetic typing were performed.
resultsTwenty-two patients with infection or colonization due to CMY-type beta-lactamase-producing E. coli and 25 patients with infection or colonization due to extended-spectrum beta-lactamase-producing E. coli were identified. The demographic characteristics of the patients were similar in both cohorts. Patients with CMY-type beta-lactamase-producing E. coli were significantly more likely to have symptomatic infection than were patients with extended-spectrum beta-lactamase-producing E. coli (P = .028). The CMY-type beta-lactamase was identified as CMY-2 or its variants. Ninety-four percent of the CMY-type beta-lactamase-producing isolates belonged to E. coli phylogenetic groups B2 and D, which are associated with virulence. Many of the isolates shared similar plasmid profiles, whereas the pulsed-field gel electrophoresis profiles were diverse. Co-resistance to non-beta-lactam antimicrobials was common.
conclusionIn Pittsburgh, Pennsylvania, CMY-type beta-lactamase-producing E. coli strains are almost as common as extended-spectrum beta-lactamase-producing E. coli strains, and they cause symptomatic infection in the majority of cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.